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Abstract
Introduction: Angiogenesis plays an important role in tumour growth, progression and invasiveness. Vascular endothelial growth factor 
(VEGF) is a recognised angiogenesis-stimulating factor. Soluble VEGF receptors (sVEGFRs) have antiangiogenic properties. Recent studies 
have indicated that serum concentrations of these factors show a good correlation with the aggressiveness of these tumours in various 
organs. The aim of this study was to assess the usefulness of determining serum concentrations of VEGF and sVEGFR-2 in patients with 
adrenal incidentalomas.
Material and methods: The study included 51 patients: 38 women aged 53.57 ± 10.12 years and 13 men aged 54.66 ± 12.73 years without 
a history of cancer but with non-functioning adrenal tumours incidentally detected on a CT scan. The analysis of the CT images included 
such morphological features of the tumour as: tumour size, tumour homogenicity, tumour density before and after administration of an in-
travenous contrast medium, and the value of percentage washout of the contrast medium from the tumour. Based on the above criteria, 
we identified a group of 40 patients with adrenal tumours who met the CT criteria for benign adenomas (Group 1) and 11 patients whose 
incidentally discovered tumours did not meet the radiological criteria for benign adenomas, thereby providing grounds for referring these 
patients for surgery (Group 2). The control group consisted of 20 healthy sex- and age-matched individuals.
Results: The mean serum concentrations of VEGF in the study and control groups were similar, although patients with adrenal tumours 
had significantly higher concentrations of sVEGFR-2 than healthy individuals. There were no significant differences in the mean concentra-
tions of VEGF and sVEGFR-2 between the patients undergoing surgery (Group 2) and the patients not undergoing surgery (Group 1), or 
between the patients undergoing surgery (Group 2) and the control group. Postoperative histopathology of the resected adrenal tumours 
revealed benign adrenocortical adenoma in eight patients and the following in the remaining patients: adrenocortical carcinoma in one 
patient, phaeochromocytoma in one patient and ganglioneuroma in one patient. The adrenocortical carcinoma patient had the highest 
concentration of VEGF, while this patient’s concentration of sVEGFR-2 was the lowest in the study group. In the patients diagnosed with 
ganglioneuroma and phaeochromocytoma, VEGF and sVEGFR-2 concentrations did not differ significantly from their mean concentra-
tions in the study group. There were also no relationships between the serum concentrations of VEGF or sVEGFR-2 and the following 
parameters: tumour size, precontrast and postcontrast tumour densities or the value of percentage washout. Positive correlations were, 
however, identified between the concentration of VEGF and the concentrations of total cholesterol and LDL-cholesterol.
Conclusions: Determining the serum concentrations of such angiogenesis markers as VEGF and sVEGFR-2 seems useful in the evalua-
tion of the nature of incidentally detected adrenal masses (incidentalomas), especially in the preoperative differential diagnosis of adrenal 
masses that do not meet the CT criteria for benign tumours. (Pol J Endocrinol 2012; 63 (1): 22–28)
Key words: adrenal incidentaloma, vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor type 2 
(sVEGFR-2)
Streszczenie
Wstęp: Nowotworzenie naczyń odgrywa istotną rolę w procesie wzrostu guza, jego progresji i inwazyjności. Uznanym czynnikiem 
stymulującym angiogenezę jest naczyniowo-śródbłonkowy czynnik wzrostu (VEGF, vascular endothelial growth factor). Rozpuszczalne 
formy receptorów dla VEGF (sVEGFR, soluble vascular endothelial growth factor receptors) wywierają działanie antyangiogenne. Badania 
prowa dzone w ostatnich latach wskazują, że stężenia tych czynników w surowicy krwi dobrze korelują z agresywnością zmian no-
wotworowych w różnych narządach. Celem pracy była ocena przydatności oznaczania stężenia naczyniowo-śródbłonkowego czynnika 
wzrostu VEGF i rozpuszczalnej formy receptora typu 2 dla tego czynnika sVEGFR2 u chorych z przypadkowo wykrytymi guzami nad-
nerczy (incydentaloma)
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Introduction
The development of modern imaging techniques, and 
their increasing accessibility, has resulted in an increased 
detectability of non-functioning adrenal tumours, also 
referred to as incidentalomas [1]. 
Most of these tumours are benign adenomas and 
are only rarely malignant. Preoperative differentiation 
between benign and malignant nature of these masses 
is difficult, and in some cases impossible. Certain di-
agnostic hints are provided by imaging studies. The 
radiological criteria that suggest the malignant nature 
of a tumour include: large tumour size, high baseline 
tumour density (expressed in Hounsfield units, HU), 
and poor washout of the contrast medium from the 
pathological lesion [2, 3]. In many cases, the radiological 
picture is equivocal, which has prompted researchers 
to look for other indicators of the malignant nature of 
incidentally detected adrenal tumours.
Previous studies have shown that the serum con-
centrations of angiogenesis markers, such as vascular 
endothelial growth factor (VEGF) and soluble vas-
cular endothelial growth factor receptors (sVEGFRs) 
show a good correlation with the aggressiveness 
of tumours in various organs and are independent 
prognostic factors [4–8]. Angiogenesis plays a par-
ticularly important role in tumour growth, progres-
sion and invasiveness. Tumours exceeding 2–3 mm in 
size require the presence of blood vessels supplying 
them with oxygen, and nutrients that allow them 
to continue to grow. VEGF stimulates the prolifera-
tion and migration of endothelial cells [9, 10]. This 
protein is a potent mitogen for endothelial cells that 
supports their survival by affecting the suppression 
of apoptotic pathways. VEGF also increases the per-
meability of blood vessels, which is a characteristic 
feature of tumour blood vessels [11]. VEGF exerts its 
actions by specific membrane receptors (VEGFRs), 
which belong to the thyrosine kinase family. One 
of these receptors is VEGFR-2. Activation of the 
membrane-bound receptor initiates a number of 
biochemical processes in endothelial cells that lead 
to cell division and the resulting formation of blood 
vessels in tumours [12]. The soluble form of this 
receptor, sVEGFR-2, shows antiangiogenic proper-
ties because, by binding with VEGF, it suppresses 
its effects on membrane-bound receptors [13, 14].
Aims
The aims of our study were to:
 — Assess the serum concentrations of VEGF and 
sVEGFR-2 in patients with incidentally detected 
non-functioning adrenal tumours (incidentalomas);
 — Assess the relationships between the serum con-
centrations of VEGF, sVEGFR-2 and the radiologi-
cal criteria for malignant/benign nature of adrenal 
tumours, such as: tumour size, tumour density and 
percentage washout on CT.
Material and methods
The study included 51 patients without a history of 
cancer but with adrenal tumours incidentally detected 
on CT: 38 women aged 53.57 ± 10.12 years and 13 men 
aged 54.66 ± 12.73 years. All the patients underwent 
an assessment of the hormonal function of their tu-
Materiał i metody: Badaniem objęto 51 chorych, w tym 38 kobiet w wieku 53,47 (SD ± 10,12) i 13 mężczyzn w wieku 54,66 (SD ± 12,73) 
roku, bez obciążeń onkologicznych, z przypadkowo wykrytymi w badaniu TK, nieczynnymi hormonalnie guzami nadnerczy. Analiza 
obrazu TK obejmowała cechy morfologiczne guza takie jak: wymiary guza, jego homogenność, gęstość przed i po dożylnym podaniu 
środka kontrastowego a także wskaźnik procentowego wypłukiwania kontrastu. W oparciu o ww. kryteria wyodrębniono grupę 40 chorych 
z guzami nadnerczy, które w badaniu TK spełniały kryteria dla łagodnych gruczolaków (grupa I) i 11 chorych, u których przypadkowo 
wykryte guzy nie spełniały radiologicznych kryteriów dla łagodnych gruczolaków, co stanowiło podstawę do skierowania tych chorych 
do  leczenia operacyjnego (grupa II). Grupę kontrolną stanowiło 20 zdrowych osób, odpowiednio dobranych pod względem płci i wieku. 
U wszystkich badanych oznaczono stężenie VEGF i sVEGFR2 w surowicy krwi. 
Wyniki: Średnie stężenie VEGF w grupie badanej i kontrolnej było podobne, stwierdzono znamiennie wyższe stężenie sVEGFR2 u chorych 
z guzami nadnerczy w porównaniu ze zdrowymi. Średnie stężenia VEGF i sVEGFR2 w grupie chorych operowanych (grupa II) nie różniły 
się istotnie od średnich stężeń w grupie chorych nieoperowanych (grupa I) i w grupie kontrolnej. Pooperacyjne badanie histopatologiczne 
guzów nadnerczy wykazało w 8 przypadkach łagodnego gruczolaka kory nadnerczy, u pozostałych chorych rozpoznano raka nadnerczy 
(1 pacjentka), guza chromochłonnego (1 pacjentka) i ganglioneuroma (1 pacjentka). U chorej z rakiem kory nadnercza stężenie VEGF było 
najwyższe, natomiast stężenie sVEGFR2 było najniższe w grupie badanej. U pacjentów z rozpoznaniem ganglioneuroma i pheochromocy-
toma stężenia VEGF i sVEGFR2 nie różniły się istotnie od średniego stężenia tych czynników w grupie badanej. Nie wykazano zależności 
pomiędzy stężeniami czynnika VEGF i sVEGFR2 a rozmiarami guza, jego densyjnością przed i po podaniu środka kontrastowego oraz 
wskaźnikiem procentowego wypłukiwania kontrastu. Stwierdzono natomiast dodatnią korelację pomiędzy stężeniem VEGF i stężeniem 
cholesterolu całkowitego i LDL-cholesterolu.
Wnioski: Oznaczenie stężenia surowiczych markerów angiogenezy VEGF i sVEGFR2 wydaje się być pomocne w ocenie charakteru 
przypadkowo wykrytych nieczynnych hormonalnie guzów nadnerczy „incydentaloma”, zwłaszcza w przedoperacyjnym różnicowaniu 
zmian nie spełniających radiologicznych kryteriów łagodności w badaniu tomografii komputerowej. (Endokrynol Pol 2012; 63 (1): 22–28)
Słowa kluczowe: incydentaloma nadnerczy, naczyniowo-śródbłonkowy czynnik wzrostu (VEGF ,vascular endothelial growth factor), rozpuszczalna 
forma receptora dla VEGF typu 2 (sVEGFR2, soluble vascular endothelial growth factor receptors type 2)
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mour, which involved determination of diurnal cortisol 
concentrations, determination of blood concentrations 
of androstenedione and dehydroepiandrosterone 
sulfate (DHEAS) and determination of free cortisol, 
aldosterone and catecholamine metabolites in 24-hour 
urine. The patients also underwent determination of 
adrenocorticotropic hormone (ACTH) in the serum 
and the lipid profile (total cholesterol, HDL-cholesterol, 
LDL-cholesterol and triglycerides). Only patients with 
non-functioning adrenal tumours were qualified for 
the study. The analysis of the CT images included such 
morphological features of the tumours as: tumour 
size, tumour homogenicity, tumour density before 
administration of the contrast medium, tumour den-
sity 60 seconds, and 15 minutes, after administration 
of the contrast medium, and the percentage washout 
of the contrast medium from the tumour. We adopted 
the commonly used radiological criteria for benign 
adenomas, i.e. tumour size below 5 cm, homogenous 
tumour structure, initial tumour density (density before 
administration of the contrast medium) below 10 HU, 
and the absolute percentage washout (APW) exceeding 
60% [3]. Based on these criteria, we divided the patients 
into two groups. 
Group 1 comprised 40 patients with adrenal 
tumours that met the CT criteria for benign adeno-
mas. Group 2 consisted of 11 patients whose inci-
dentalomas did not meet the radiological criteria for 
benign adenomas, thus providing grounds to refer 
these patients for surgery.
The control group comprised 20 healthy sex- and 
age-matched individuals. All the patients underwent 
determination of serum VEGF and sVEGFR-2 by 
enzyme immunoassay (ELISA) with the use of com-
mercially available kits (Human VEGF, Human 
sVEG-FR2/KDR/Flk-1, R&D Systems Europe Ltd.).
Statistical analysis
The investigated parameters (expressed as means ± stand-
ard deviations) were compared with the t-Student test, 
and the analysis of correlation was performed using the 
Pearson’s method. Differences with p values below 0.05 
were considered statistically significant.
Results
The mean serum concentrations of VEGF in the study 
and control groups were similar, although patients with 
adrenal tumours had significantly higher concentrations 
of sVEGFR-2 than healthy individuals (Table I).
There were no significant differences in the mean 
concentrations of VEGF and sVEGFR-2 between the 
patients undergoing surgery (Group 2) and the patients 
not undergoing surgery (Group 1), or between the 
patients undergoing surgery (Group 2) and the control 
group (Table II).
Postoperative histopathology of the resected adre-
nal tumours that did not meet the radiological criteria 
for benign nature revealed benign adrenocortical 
adenoma in eight patients, and the following in the 
remaining three patients: adrenocortical carcinoma in 
one patient, phaeochromocytoma in one patient and 
ganglioneuroma in one patient. The concentration of 
VEGF in the adrenocortical carcinoma patient equalled 
Table I. Comparison of the concentrations of VEGF and sVEGFR-2 in the study and control groups
Tabela I. Porównanie stężeń VEGF i sVEGFR 2 w grupie badanej i grupie kontrolnej
Study group Control group p
n Mean SD SEM n Mean SD SEM
VEGF
51
300.369 218.8228 30.6413
22
328.909 234.5201 38.9806 NS
sVEGFR-2 7,566.553 1,674.8084 234.5201 6,577.591 1,413.0904 301.2719 0.018
Table II. Comparison of the mean concentrations of VEGF and sVEGFR-2 between the group of patients meeting the radiological 
criteria for benign tumours on CT (group 1) and the group of patients not meeting these criteria (group 2)
Tabela II. Porównanie średnich stężeń VEGF i sVEGFR2 pomiędzy grupą chorych z guzami nadnerczy, które spełniają 
radiologiczne kryteria łagodności guza w badaniu TK (Grupa I) i nie spełniają tych kryteriów (Grupa II)
Group 1 Group 2 p
n Mean SD SEM n Mean SD SEM
VEGF
40
292.018 212.9189 33.6654
11
330.736 247.6272 74.6624 NS
sVEGFR-2 7,603.715 1,730.9524 273.6876 7,431.418 1,521.2293 458.6679 NS
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766.1 pg/ml and was the highest in the study group, 
while the concentration of sVEGFR-2 in this patient 
equalled 6,843.5 pg/ml and was the lowest in the study 
group. In the patients diagnosed with ganglioneuroma 
and phaeochromocytoma, VEGF and sVEGFR-2 con-
centrations did not differ significantly from their mean 
concentrations in the study group.
There was no correlation between the concentra-
tions of VEGF and sVEGFR-2 and the following pa-
rameters: tumour size, tumour density before admin-
istration of the contrast medium, tumour density after 
administration of the contrast medium and percentage 
washout (Table III). A positive correlation was, however, 
observed between the concentration of VEGF and the 
concentration of total cholesterol (Figure 1) and between 
the concentration of VEGF and the concentration of 
LDL-cholesterol (Figure 2).
Discussion
Incidentally discovered adrenal mass, first described 
by Geelhoed and Spiegel in 1981, continue to pose 
a considerable diagnostic challenge for clinicians. Ad-
renal tumours are discovered in 4–6% of patients who 
undergo imaging studies that involve these organs 
[15, 16]. They are mainly benign tumours with the 
predominant type being adenomas (non-functioning 
adenomas (94%), cortisol-secreting adenomas (5%) 
and aldosterone-secreting adenomas (1%). The other 
benign tumours include myelolipoma (9%), cysts, 
ganglioneuroma, haemangioma, neuroblastoma, 
haemorrhagic changes and granulomatous diseases, 
which account for 1–2% of all benign lesions. Among 
the lesions of the incidentaloma type, which is much 
less frequent, are: primary adrenocortical carcinoma 
Table III. Correlations between the concentrations of VEGF and sVEGFR-2 and age, tumour size, precontrast tumour density 
and percentage washout
Tabela III. Korelacja pomiędzy stężeniem VEGF i sVEGFR2 a wiekiem, rozmiarami guza, densyjnością guza przed podaniem 
kontrastu i wskaźnikiem procentowego wypłukiwania kontrastu
Age Maximum tumour size Precontrast density Percentage washout
VEGF r 0.10 –0.07 0.18 –0.002
p 0.36 0.59 0.19 0.985
n 73 51 51 51
sVEGFR-2 r 0.06 0.12 0.13 0.15
p 0.60 0.38 0.34 0.28
n 73 51 51 51
r — correlation coefficient; n — number of subjects; p — statistical significance level
Figure 1. Correlation between the concentration of VEGF and 
that of total cholesterol (p = 0.008)
Rycina 1. Korelacja pomiędzy stężeniem VEGF i cholesterolu 
całkowitego (p = 0,008)
Figure 2. Correlation between the concentration of VEGF and 
that of LDL-cholesterol (p = 0.011)
Rycina 2. Korelacja pomiędzy stężeniem VEGF i LDL-cholesterolu 
(p = 0,011)
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(2–10%), phaeochromocytoma (5–8%) and metastatic 
foci of other cancers [17, 18]. 
A Polish study of 1,790 patients with accidentally 
discovered adrenal tumours revealed adrenal carcinoma 
in 7.5% of the patients [19]. Due to the different manage-
ment and prognosis in functioning and non-functioning 
adenomas and in adrenal carcinomas, a thorough dif-
ferential diagnosis in the preoperative period is of the 
utmost importance, with imaging studies, mainly com-
puted tomography, playing the key role. Large tumours 
(exceeding 5–6 cm), irregular outlines and the presence 
of regressive lesions such as extravasation, necrosis, 
fibrosis and calcification within the tumour, all point to 
its malignant nature. An additional indicator of malig-
nancy is a rapid tumour growth dynamic in subsequent 
imaging studies [16, 20]. Another radiological feature 
of the malignant nature of tumours is a high density of 
the tumour on CT without contrast (> 10 HU), which 
indicates a low content of fat. In contrast to malignant 
lesions, most benign adenomas (about 70%) contain 
intracellular fat (mainly cholesterol and fatty acids) and 
are therefore characterised by a low density (< 10 HU) 
[2, 21]. Dynamic studies using contrast provide additional 
information that makes differentiation between benign 
and malignant lesions easier. Adrenocortical carcinoma 
is characterised by a high baseline density, a strong con-
trast enhancement during the enhancement phase, and 
a low washout of the contrast in the delayed phase. The 
percentage washout of the contrast in adrenocortical 
carcinoma is lower than 50%, while in benign tumours 
it usually exceeds 60% [22]. Assuming a threshold value 
of 10 HU for tumour density before administration of the 
contrast medium, and 60% for the percentage washout 
of the contrast medium, the sensitivity and specificity of 
computed tomography in diagnosing benign adenomas 
is 98% and 92%, respectively [23].
Based on the above criteria, we qualified for surgery 
11 patients with adrenal tumours of the incidentaloma 
type. Adrenal tumours in this group of patients were 
characterised, on CT scans, by large sizes ranging from 
2 cm to 12 cm (mean 7 cm), non-homogenous structure, 
high baseline density (> 10 HU), and a percentage 
washout below 50%. 
However, in one case, histopathology revealed 
an adrenocortical carcinoma. It was a tumour measuring 
5.2 × 5.0 cm, with a non-homogenous structure with 
calcifications, high density before and after contrast, 
and a percentage washout of 22%. 
In one patient, a diagnosis of clinically asymptomatic 
phaeochromocytoma was made with normal concen-
trations of methoxycatecholamines in 24-hour urine. 
In one case, histopathological examination of the 
resected adrenal gland revealed a benign lesion, namely 
ganglioneuroma. 
In the remaining eight patients who had undergone 
unilateral adrenalectomy, benign adenomas were diag-
nosed, although in the preoperative CT scans these tu-
mours had not met the criteria for benign lesions. They 
were most probably lipid-poor adenomas, which ac-
count for 10–40% of all benign adrenal adenomas. These 
tumours are characterised by a higher density before 
and after administration of the contrast medium com-
pared to lipid-rich adenomas, although the percentage 
washout in both these adenoma types is usually similar 
[2]. In our study, baseline tumour density in the pre-
operative period exceeded 10 HU and the percentage 
washout was lower than 50%, which raised concerns 
that these tumours might be malignant. In some cases, 
preoperative differentiation of lipid-poor adenomas, 
carcinomas and non-adenomas of the adrenal gland is 
difficult, and additional diagnostic studies are required. 
It seems that the assessment of neoangiogenesis in 
these cases may play a significant role. VEGF, discovered 
in 1989, is a key angiogenic cytokine [11]. Exerting its 
action through specific membrane-bound VEGFRs, it 
stimulates the development of new blood vessels neces-
sary for the growth of solid tumours in various organs, 
including endocrine glands [24–27]. An important 
angiogenesis regulatory role is played by the soluble 
form of type 2 VEGF receptor (sVEGFR-2). This recep-
tor, as a result of VEGF binding, decreases its effects on 
membrane-bound receptors in endothelial cells, contrib-
uting to the suppression of angiogenesis [13, 14]. In our 
study, we attempted to establish whether determination 
of serum VEGF and sVEGFR-2 concentrations could 
be useful in the preoperative differential diagnosis of 
accidentally detected adrenal tumours. We found no 
differences in mean VEGF concentration between the 
study and control groups. 
It should be noted, however, that the study group 
mainly comprised patients with the diagnosis of be-
nign adenoma (48 patients): in 40 of these patients, the 
diagnosis had been made on the basis of the radiologi-
cal criteria for the benign nature of the tumour on CT, 
while in the other eight the diagnosis had been based on 
postoperative histopathological examination. The lack 
of difference in the concentration of VEGF between the 
group of patients with benign adenomas and healthy 
individuals, which we observed, is consistent with other 
studies [27, 28].
We also found no differences in the concentrations 
of VEGF and sVEGFR-2 between the group of 11 pa-
tients undergoing adrenalectomy due to failure to meet 
the radiological criteria for the benign nature of their 
tumours, and the group of patients whose CT scans 
unequivocally revealed benign adrenal adenomas. Most 
of the resected adrenal tumours (eight out of 11) were 
benign lipid-poor adenomas.
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Some authors have demonstrated a significantly 
higher serum concentration of VEGF and, at the same 
time, a significantly lower serum concentration of 
sVEGFR-2, in patients with adrenal cancer compared 
to patients with benign adenomas [24, 25]. Likewise, 
in our study, the patient with adrenocortical carcinoma 
had the highest concentration of VEGF and the lowest 
concentration of sVEGFR-2 in the study group. In the 
cases of phaeochromocytoma and ganglioneuroma, the 
concentrations of VEGF and sVEGFR-2 did not differ 
significantly from the study group. According to other 
authors, the concentration of VEGF is significantly 
higher in patients with functioning adrenal adenomas, 
including phaeochromocytoma, compared to healthy 
individuals [24, 29].
Our results indicate that the concentrations of 
VEGF and sVEGFR-2 are similar in both lipid-rich and 
lipid-poor benign adenomas. Hence, the determination 
of these factors may be helpful in the differential diagno-
sis of adrenal tumours that do not meet the radiological 
criteria for benign character on CT. 
These results should, however, be interpreted 
with caution due to the small number of subjects. In 
addition, lipid-rich adrenal tumours were not veri-
fied histopathologically and the diagnosis of benign 
adenoma in these cases was based solely on radio-
logical criteria.
We found no correlation between VEGF or sVEGFR-2 
and tumour size, which is consistent with other studies 
[26]. We also found no relationship between the con-
centration of these factors and tumour density or the 
percentage washout of the contrast medium from the 
tumour on dynamic CT imaging. This could result from 
the fact that the study group was quite homogenous in 
terms of diagnosis (in 94% of the patients, the diagnosis 
of benign adrenal adenoma was made). It would be 
interesting to look for a relationship between serum 
markers of angiogenesis and the radiological criteria 
for malignant nature of the tumours in the group of 
patients with histopathologically confirmed adreno-
cortical carcinoma.
The results of the determination of sVEGFR-2 
were quite surprising. The mean concentration of 
this antiangiogenic molecule in the group of patients 
with adrenal incidentalomas was significantly higher 
than that in the control group, while other authors 
have observed significantly lower mean sVEGFR-2 
concentrations in patients with benign adrenal ad-
enomas [27].
The positive correlation between the concentration 
of VEGF and the concentration of total cholesterol, 
and between the concentration of VEGF and the con-
centration of LDL-cholesterol, probably results from 
overexpression of VEGF in endothelial cells secondary 
to hypoxia and blood vessel wall inflammation in the 
early period of atherogenesis. The atherogenic effects 
of VEGF result from increased permeability of the 
endothelium, increased migration of neutrophils, and 
stimulation of endothelial cell proliferation, which ini-
tiates atherogenesis [30–32].
In conclusion, determining serum markers of 
angiogenesis, VEGF and sVEGFR-2 would seem to 
be helpful in assessing the nature of accidentally 
detected non-functioning adrenal tumours of the 
incidentaloma type, especially in the preoperative 
differentiation of lesions that do not meet the ra-
diological criteria for benign lesions on computed 
tomography.
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